Explore the vast range of titles available.

In this study, we present the multiple detection of respiratory viruses in infants during primary respiratory illness, investigate the sensitivity of nasal swabs and nasopharyngeal aspirates, and assess whether patient characteristics and viral load played a role in the sensitivity. Healthy infants were included at signs of first respiratory tract infection. Paired nasopharyngeal aspirates and nasal swabs were collected. Real-time polymerase chain reaction (PCR) was carried out for 11 respiratory pathogens. Paired nasopharyngeal aspirates and nasal swabs were collected in 98 infants. Rhinovirus (n = 67) and respiratory syncytial virus (n = 39) were the most frequently detected. Co-infection occurred in 48% (n = 45) of the infants. The sensitivity of the nasal swab was lower than the nasopharyngeal aspirate, in particular, for respiratory syncytial virus (51% vs. 100%) and rhinovirus (75% vs. 97%). The sensitivity of the nasal swab was strongly determined by the cycle threshold (CT) value (p < 0.001). The sensitivity of the swab for respiratory syncytial virus, but not rhinovirus, was 100% in children with severe symptoms (score ≥11). It is concluded that, for community-based studies and surveillance purposes, the nasal swab can be used, though the sensitivity is lower than the aspirate, in particular, for the detection of mild cases of respiratory syncytial virus (RSV) infection.

Due to environmental reasons and the shortage of natural resources, it is greatly valuable to recycle construction and demolition waste (CDW) as much as possible. One of effective ways to reuse more CDW is to produce a cemented road base material. The recycled CDW however is a mix of recycled masonry and concrete with a wide variation in composition. This implies that the mechanical properties of cement treated demolition waste are not only determined by cement content and degree of compaction, but also by the ratio of crushed masonry content to crushed concrete content. In order to optimize its mixture proportioning, this paper explores the response surface and contour plot of the combined effect of mixture variables on the mechanical properties including the unconfined compressive strength (UCS), the elastic modulus ( E ) and their ratio. It has been recognized that optimizing the mixture proportioning of cement treated demolition waste should not only consider its material properties, but also needs to take into account its structural behavior as a pavement layer. Analytical results indicate that increasing the degree of compaction is an economic technique to obtain the required strength, but it is not an efficient method to enhance the admissible elastic strain (the ratio of UCS to E ) and to improve the flexural rigidity of the road base layer. Obtaining a desired low flexural rigidity certainly needs adjusting of the masonry content and the cement content.

This paper presents the shrinkage cracking characteristics of cement treated demolition waste as a road base layer, which was produced by using recycled crushed concrete and masonry aggregates from construction and demolition waste (CDW). The developed method to estimate the crack pattern was based on the structural properties of cement treated demolition waste measured in the laboratory and the average climatic conditions recorded in the Netherlands. The influences of four mixture variables (masonry content, moisture content, cement content and degree of compaction) on the crack pattern were investigated. Results show that the proposed estimation model can predict the crack pattern of cement treated demolition waste comparable to the crack spacing observed in the field. The masonry variation in CDW is a key factor to determine its shrinkage cracking characteristics.

The treatment of choice of H. pylori infections is a 7-day triple-therapy with a proton pump inhibitor (PPI) plus amoxicillin and either clarithromycin or metronidazole, depending on local antibiotic resistance rates. The data on efficacy of eradication therapy in a group of rheumatology patients on long-term NSAID therapy are reported here. This study was part of a nationwide, multicenter RCT that took place in 2000–2002 in the Netherlands. Patients who tested positive for H. pylori IgG antibodies were included and randomly assigned to either eradication PPI-triple therapy or placebo. After completion, follow-up at 3 months was done by endoscopy and biopsies were sent for culture and histology. In the eradication group 13% (20/152, 95% CI 9–20%) and in the placebo group 79% (123/155, 95% CI 72–85%) of the patients were H. pylori positive by histology or culture. H. pylori was successfully eradicated in 91% of the patients who were fully compliant to therapy, compared to 50% of those who were not (difference of 41%; 95% CI 18–63%). Resistance percentages found in isolates of the placebo group were: 4% to clarithromycin, 19% to metronidazole, 1% to amoxicillin and 2% to tetracycline.

Preference for a drug formulation is important in adherence to long-term medication for chronic illnesses such as osteoporosis. We investigated the preference for and acceptability of chewable tablet containing calcium and vitamin D (Calci Chew D₃, Nycomed) compared to that of a sachet containing calcium and vitamin D₃ (Cad, Will-Pharma). This open, randomised, cross-over trial was set up to compare the preference and acceptability of two calcium plus vitamin D₃ formulations (both with 500 mg calcium and 400/440 IU vitamin D3), given twice a day in patients with osteoporosis. Preference and acceptability were assessed by means of questionnaires. Preference was determined by asking the question, which treatment the patient preferred, and acceptability was measured by scoring five variables, using rating scales. Of the 102 patients indicating a preference for a trial medication, 67% preferred the chewable tablet, 19% the sachet with calcium and vitamin D₃, and 15% stated no preference. The significant preference for Calci Chew D₃ (p < 0.0001) was associated with higher scores for all five acceptability variables. The two formulations were tolerated equally well. A significant greater number of patients considered the chewable tablet as preferable and acceptable to the sachet, containing calcium and vitamin D₃. Trial registration: Current Controlled Trials ISRCTN18822358.

Two cases are presented in which repeated use of the TNF-alpha blocker infliximab may have led to development of pustular skin lesions. These findings might result in an improved understanding regarding the safety of infliximab with long-term usage.

To enhance the performance of mix granulate road base courses by cement treatment. The mechanical properties of cement treated mix granulate （CTMG） were studied, which was designed with 65% crushed masonry and 35% crushed concrete by mass. The central composite design was employed to prepare specimens with different levels of cement content and degree of compaction. All specimens were cured in a fog room at 20 ℃ for a specific number of days. The compressive strength and the indirect tensile strength were determined through the monotonic compression and indirect tension tests. Effective prediction models for the mechanical properties of CTMG, in relation to the cement content, the degree of compaction and the curing time, were successfully established for a mix containing 65% crushed masonry and 35% crushed concrete by mass.

To investigate whether sodium fluoride (NaF) is able to prevent bone loss in patients treated with corticosteroids (Cs), we performed a randomized double-masked, placebo-controlled trial with 44 Cs-treated patients without established osteoporosis, defined as the absence of previous peripheral fractures and vertebral deformities on radiographs. The effects of NaF (25 mg twice daily) and placebo on the bone mineral density (BMD) of the lumbar spine and hips were compared at baseline and at 6, 12, 18 and 24 months. After 2 years, the BMD of the lumbar spine had decreased in the placebo group by 3.0% (95% CI: -4.9% to -1.0%; p < 0.01); in the NaF group there was a statistically insignificant increase in BMD of 2.2% (95% CI: -0.8% to +5.3%). The difference in the changes in BMD between the two groups was +5.2% (95% CI: +1.8% to +8.6%; p < 0.01). In the hips, BMD had decreased after 2 years in both groups: in the placebo group by -3.0% (95% CI: -5.0% to -1.0%; p < 0.05) and in the NaF group by 3.8% (95% CI: -6.1% to -1.5%; p < 0.01). The difference in the changes in BMD between the two groups was not significant: +0.8% (95% CI: -2.1% to +3.8%). Three vertebral deformities were observed in the placebo group and one in the NaF group (insignificant difference), while no peripheral fractures occurred during the study period. It is concluded that in Cs-treated patients without established osteoporosis NaF prevents bone loss in the lumbar spine but does not have a positive effect on the BMD of the hips.

OBJECTIVE To investigate whether administration of sodium fluoride (NaF) in addition to cyclical etidronate has a positive effect on bone mineral density (BMD) in patients with established osteoporosis during continued treatment with corticosteroids. PATIENTS AND METHODS 47 patients who were receiving treatment with corticosteroids were included in a two year randomised, double blind, placebo controlled trial. Established osteoporosis was defined as a history of a peripheral fracture or a vertebral deformity, or both, on a radiograph. All patients were treated with cyclical etidronate, calcium, and either NaF (25 twice daily) or placebo. Vitamin D was supplemented in the case of a low serum 25 (OH) vitamin D concentration. BMD of the lumbar spine and hips was measured at baseline and at 6, 12, 18, and 24 months. RESULTS After two years of treatment, the BMD of the lumbar spine in the etidronate/NaF group had increased by +9.3% (95% confidence intervals (CI): +2.3% to +16.2%, p<0.01), while the BMD in the etidronate/placebo group was unchanged: +0.3% (95% CI: −2.2% to +2.8%). The difference in the change in BMD between groups was +8.9% (95% CI: +1.9% to +16.0%, p<0.01). For the hips, no significant changes in BMD were observed in the etidronate/NaF group after two years: −2.5% (95% CI: −6.8% to +1.8%); in the etidronate/placebo group BMD had significantly decreased: −4.0% (95% CI: −6.6% to −1.4%; p<0.01). The difference between the groups was not significant: +1.5% (95% CI: −3.4% to +6.4%). No significant differences in number of vertebral deformities and peripheral fractures were observed between the two groups. CONCLUSION The effect of combination treatment with NaF and etidronate on the BMD of the lumbar spine in corticosteroid treated patients with established osteoporosis is superior to that of etidronate alone.

While repeating fast radio bursts (FRBs) remain scarce in number, they provide a unique opportunity for follow-up observations that enhance our knowledge of their sources and potentially of the FRB population as a whole. Attaining more burst spectra could lead to a better understanding of the origin of these bright, millisecond-duration radio pulses. We therefore performed \\(\\sim\\)20 hr of simultaneous observations on FRB 121102 with the Effelsberg 100-m radio telescope and the Low Frequency Array (LOFAR) to constrain the spectral behaviour of bursts from FRB 121102 at 1.4 GHz and 150 MHz. This campaign resulted in the detection of nine new bursts at 1.4 GHz but no simultaneous detections with LOFAR. Assuming that the ratio of the fluence at two frequencies scales as a power law, we placed a lower limit of \\(\\alpha\\) > -1.2 \\(\\pm\\) 0.4 on the spectral index for the fluence of the instantaneous broad band emission of FRB 121102. For the derivation of this limit, a realistic fluence detection threshold for LOFAR was determined empirically assuming a burst would be scattered as predicted by the NE2001 model. A significant variation was observed in the burst repeat rate R at L-band. During observations in September 2016, nine bursts were detected, giving R = 1.1 \\(\\pm\\) 0.4 hr\\(^{-1}\\), while in November no bursts were detected, yielding R < 0.3 hr\\(^{-1}\\) (95% confidence limit). This variation is consistent with earlier seen episodic emission of FRB 121102. In a blind and targeted search, no bursts were found with LOFAR at 150 MHz, resulting in a repeat rate limit of R < 0.16 hr\\(^{-1}\\) (95% confidence limit). Burst repeat rate ratios of FRB 121102 at 3, 2, 1.4, and 0.15 GHz are consistent within the uncertainties with a flattening of its spectrum below 1 GHz.